Effect of dual tocolysis with fenoterol and atosiban in human myometrium.


Journal

Journal of perinatal medicine
ISSN: 1619-3997
Titre abrégé: J Perinat Med
Pays: Germany
ID NLM: 0361031

Informations de publication

Date de publication:
25 Feb 2019
Historique:
received: 07 01 2018
accepted: 14 08 2018
pubmed: 16 9 2018
medline: 18 5 2019
entrez: 16 9 2018
Statut: ppublish

Résumé

Objectives To measure the tocolytic effect of the combination of the oxytocin receptor antagonist atosiban with the β-mimetic agent fenoterol on human myometrium of pregnant women. Methods An in vitro study of contractility in human myometrium at the Laboratory of the Department of Obstetrics, University Hospital of Zürich, Switzerland, was performed. Thirty-six human myometrial biopsies were obtained during elective caesarean sections of singleton pregnancies at term. Tissue samples were exposed to atosiban, fenoterol and the combination of atosiban with fenoterol. Contractility was measured as area under the curve during 30 min of spontaneous contractions. The effect of treatment was expressed as the percentage of change from basal activity during 30 min of exposure. Differences were calculated using a paired Wilcoxon signed-rank test. An additive effect of dual tocolysis was assumed when no significant difference was detected between the observed and expected inhibition of dual tocolysis. When inhibition was greater or lower than expected, the dual combination was characterised as "synergistic" or "antagonistic", respectively. Results Atosiban and fenoterol alone suppressed contractions by a median of 43.2% and 29.8%, respectively. The combination of atosiban plus fenoterol was measured at a level of 67.3% inhibition. There was no significant difference in the expected (63.2%) and observed inhibition effect of dual tocolysis (P=0.945). Conclusion This study demonstrated an additive effect of dual tocolysis of atosiban and fenoterol on human myometrium in vitro, but no synergistic or antagonistic effect.

Identifiants

pubmed: 30218606
doi: 10.1515/jpm-2018-0010
pii: jpm-2018-0010
doi:

Substances chimiques

Tocolytic Agents 0
atosiban 081D12SI0Z
Fenoterol 22M9P70OQ9
Vasotocin W6S6URY8OF

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-194

Références

Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–72.
Lawn JE, Kerber K, Enweronu-Laryea C, Cousens S. 3.6 Million neonatal deaths – what is progressing and what is not? Semin Perinatol 2010;34:371–86.
Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. Br Med J 2006;332:937–9.
Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94: 869–77.
Caritis S. Adverse effects of tocolytic therapy. BJOG 2005;112(Suppl 1):74–8.
Doret M, Mellier G, Gaucherand P, Saade GR, Benchaib M, Frutoso J, et al. The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. BJOG 2003;110:731–4.
Wachter R, Brenneisen R, Hamburger M, Mennet M, Schnelle M, Worel AM, et al. Leaf press juice from Bryophyllum pinnatum (Lamarck) Oken induces myometrial relaxation. Phytomedicine 2011;19:74–82.
Gwehenberger B, Rist L, Huch R, von Mandach U. Effect of Bryophyllum pinnatum versus fenoterol on uterine contractility. Eur J Obstet Gynecol Reprod Biol 2004;113:164–71.
Goodwin TM, Valenzuela GJ, Silver H, Creasy G. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group. Obstet Gynecol 1996;88:331–6.
von Mandach U, Boni R, Danko J, Huch R, Huch A. Pharmacokinetics of fenoterol in pregnant women. Arzneimittelforschung 1995;45:186–9.
Kuc P, Laudanski P, Pierzynski P, Laudanski T. The effect of combined tocolysis on in vitro uterine contractility in preterm labour. Adv Med Sci 2011;56:88–94.
Arrowsmith S, Neilson J, Wray S. The combination tocolytic effect of MgSO4 and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. Am J Obstet Gynecol 2016;215:e1–9.
Buscher U, Chen FC, Riesenkampff E, von Dehn D, David M, Dudenhausen JW. Effects of oxytocin receptor antagonist atosiban on pregnant myometrium in vitro. Obstet Gynecol 2001;98:117–21.
Carvajal JA, Zambrano MJ, Theodor NM, Moreno LE, Olguin TR, Vanhauwaert PS, et al. The synergic in vitro tocolytic effect of nifedipine plus ritodrine on human myometrial contractility. Reprod Sci 2017;24:635–40.
Romero R, Mazor M, Munoz H, Gomez R, Galasso M, Sherer DM. The preterm labor syndrome. Ann N Y Acad Sci 1994;734: 414–29.
Anotayanonth S, Subhedar NV, Garner P, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004;4:CD004352.
Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy GW, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol 1996;13:143–6.
Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev 2014;7:Cd006169.
Ng QJ, Abdul Rahman MF, Lim ML, Chee JJ, Tan KH. Single versus combination tocolytic regimen in the prevention of preterm births in women: a prospective cohort study. J Perinat Med 2015;43:423–8.
Gallagher LA, Gautieri RF. Influence of a combination of ritodrine and nifedipine on the isolated rat uterus. Res Commun Chem Pathol Pharmacol 1992;75:3–18.
Saade GR, Taskin O, Belfort MA, Erturan B, Moise KJ Jr. In vitro comparison of four tocolytic agents, alone and in combination. Obstet Gynecol 1994;84:374–8.
Doret M, Mellier G, Benchaib M, Piacenza JM, Gharib C, Pasquier JC. In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. BJOG 2002;109:983–8.
Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021–9.
Rasmussen BB, Larsen LS, Senderovitz T. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. BJOG 2005;112:1492–9.
Yulia A, Johnson MR. Myometrial oxytocin receptor expression and intracellular pathways. Minerva Ginecol 2014;66: 267–80.

Auteurs

Bernhard Stoiber (B)

Department of Obstetrics and Gynecology, Danube Hospital, SMZ Ost, Langobardenstr. 122, Vienna 1220, Austria.

Christian Haslinger (C)

Division of Obstetrics, University Hospital of Zürich, Zurich, Switzerland.

Marie Kristin Schäffer (MK)

Division of Obstetrics, University Hospital of Zürich, Zurich, Switzerland.

Roland Zimmermann (R)

Division of Obstetrics, University Hospital of Zürich, Zurich, Switzerland.

Leonhard Schäffer (L)

Division of Obstetrics, Cantonal Hospital, Baden, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH